Healthy volunteers help test new granule version of CF drugs
NCT ID NCT06299709
First seen Oct 31, 2025 · Last updated Jun 16, 2026 · Updated 33 times
Summary
This early-stage study tested how a new granule (powder) form of three cystic fibrosis drugs (vanzacaftor, tezacaftor, and deutivacaftor) is absorbed by the body. It involved 34 healthy adults and looked at the effects of food and different doses. The goal was to gather information, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion, Inc.
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.